CN Patent

CN104109159A — 苯磺酰胺噻唑化合物的新晶型及其制备方法

Assigned to Hangzhou Pushai Pharmaceutical Technology Co Ltd · Expires 2014-10-22 · 12y expired

What this patent protects

本发明涉及苯磺酰胺噻唑化合物的新晶型及其制备方法。具体而言，本发明涉及化合物N-[3-[5-(2-氨基-4-嘧啶基)-2-(叔丁基)-4-噻唑基]-2-氟苯基]-2,6-二氟苯磺酰胺的多种新晶型。本发明所述新晶型具有在室温条件或在含水体系中更稳定的优点，因此相对于现有的晶型，具有更好的稳定性。

USPTO Abstract

本发明涉及苯磺酰胺噻唑化合物的新晶型及其制备方法。具体而言，本发明涉及化合物N-[3-[5-(2-氨基-4-嘧啶基)-2-(叔丁基)-4-噻唑基]-2-氟苯基]-2,6-二氟苯磺酰胺的多种新晶型。本发明所述新晶型具有在室温条件或在含水体系中更稳定的优点，因此相对于现有的晶型，具有更好的稳定性。

Drugs covered by this patent

dabrafenib-mesylate (DABRAFENIB MESYLATE)

Patent Metadata

Patent number: CN104109159A
Jurisdiction: CN
Classification: —
Expires: 2014-10-22
Drug substance claim: No
Drug product claim: No
Assignee: Hangzhou Pushai Pharmaceutical Technology Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.